Abstract | PURPOSE: METHOD: RESULTS:
Rosiglitazone resulted in slow accrual of limb fat detected by DXA (+444 +/- 186 g; p < .05) but not CT. Pravastatin had no consistent significant effects on body composition, although it reduced total and LDL cholesterol. Negative interactions were observed between pravastatin and rosiglitazone. rhGH reduced abdominal fat by CT (-31 +/- 15 cm2, 26%; p < .05) and DXA (-1597 +/- 383 g, 27%; p < .05) and increased trunk and limb lean mass (+10% and +12%, respectively). However, effects largely disappeared within 12 weeks post treatment. rhGH alone impaired insulin sensitivity but not when combined with rosiglitazone. CONCLUSION: Prolonged rosiglitazone treatment slowly improves lipoatrophy. rhGH rapidly and selectively reduces visceral fat, although effects are short-lived; co-administered rosiglitazone abrogates rhGH-related insulin resistance.
|
Authors | Derek C Macallan, Christine Baldwin, Sundihya Mandalia, Vjera Pandol-Kaljevic, Nadine Higgins, Alan Grundy, Graeme J Moyle |
Journal | HIV clinical trials
(HIV Clin Trials)
2008 Jul-Aug
Vol. 9
Issue 4
Pg. 254-68
ISSN: 1528-4336 [Print] England |
PMID | 18753120
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Fats
- Recombinant Proteins
- Thiazolidinediones
- Rosiglitazone
- Human Growth Hormone
- Pravastatin
|
Topics |
- Absorptiometry, Photon
- Adult
- Body Composition
(drug effects)
- Drug Therapy, Combination
- Endpoint Determination
- Fats
(metabolism)
- Female
- HIV-1
- HIV-Associated Lipodystrophy Syndrome
(drug therapy)
- Human Growth Hormone
(therapeutic use)
- Humans
- London
- Male
- Pilot Projects
- Pravastatin
(therapeutic use)
- Prospective Studies
- Recombinant Proteins
(therapeutic use)
- Rosiglitazone
- Thiazolidinediones
(therapeutic use)
- Tomography, X-Ray Computed
- Treatment Outcome
|